

IN THE CLAIMS:

Please amend claims 40 to 49 as follows:

40. (Once Amended) An [antivenin] antivenom composition comprising [F(ab)] Fab fragments which bind specifically to a venom of a [species] snake of the Crotalus genus and which are essentially free from contaminating Fc as [judged] determined by immunoelectrophoresis using anti-Fc antibodies, and a pharmaceutically acceptable carrier, wherein said venom comprises more than one toxin.

41. (Once Amended) The antivenin composition of claim 40, wherein an antibody source for [the F(ab)] said Fab fragments is IgG(T).

42. (Once Amended) The antivenin composition of claim 40, wherein an antibody source for [the F(ab)] said Fab fragments is polyvalent IgG(T).

43. (Once Amended) The antivenin composition of claim 40, wherein said [F(ab)] Fab fragments are derived from IgG(T).

44. The antivenin composition of claim 40, wherein said [F(ab)] Fab fragments are derived from polyvalent IgG(T).

45. (Once Amended) [F(ab)] Fab fragments which bind specifically to a venom of a [species] snake of the Crotalus genus, and which are essentially free from contaminating Fc as [judged] determined by immunoelectrophoresis using an anti-Fc antibody, wherein said venom comprises more than one toxin.

46. (Once Amended) The [F(ab)] Fab fragments of claim 45, wherein an antibody source for [the F(ab)] said Fab fragments is IgG(T).

47. (Once Amended) The [F(ab)] Fab fragments of claim 45, wherein an antibody source for [the F(ab)] said Fab fragments is polyvalent IgG(T).

48. (Once Amended) The [F(ab)] Fab fragments of claim 45, wherein said [F(ab)] Fab fragments are derived from IgG(T).

49. (Once Amended) The [F(ab)] Fab fragments of claim 45, wherein said [F(ab)] Fab fragments are derived from polyvalent IgG(T).

Please add the following new claims 50-60 as follows:

--50. A antivenom composition comprising Fab fragments, which bind specifically to a venom of a snake of the Crotalidae family, and which are essentially free from contaminating Fc as determined by immunoelectrophoresis using anti-Fc antibodies, and a pharmaceutically acceptable carrier.

51. The antivenom composition of claim 50, wherein an antibody source for said Fab fragments is IgG(T).

52. The antivenom composition of claim 50, wherein an antibody source for said Fab fragments is polyvalent IgG(T).

53. The antivenom composition of claim 50, wherein said Fab fragments are derived from IgG(T).

54. The antivenom composition of claim 50, wherein said Fab fragments are derived from polyvalent IgG(T).